What Salus BioMed does

Salus BioMed (深圳赛陆医疗科技有限公司) is a Shenzhen-headquartered Chinese life sciences tools company developing proprietary next-generation gene sequencing platforms and spatial omics solutions. Founded around 2020-2022 with 51-100 employees and headquartered in Shenzhen's Guangming District, the company has built a complete sequencing product line covering low-throughput (Saluseq Nimbo, with 3.4-hour rapid sequencing), mid-throughput (Salus Pro, supporting 80M-1000M reads and multiple read lengths), and high-throughput (Salus EVO) instruments, plus the SalusSTS spatial transcriptomics solution achieving approximately 1 micrometer resolution through integration of high-throughput sequencing with super-resolution fluorescence imaging. The underlying chemistry is based on the reversible terminator method, developed and manufactured in-house.

The company serves clinical diagnostics (reproductive health, tumor diagnosis, infectious disease control, large health screening), academic and life sciences research, public health and biosafety, molecular breeding, and consumer genetics customers across China with international expansion into Thailand and the Middle East. Revenue derives primarily from hardware sales of sequencing instruments and recurring consumables/reagents, following the standard razor-and-blade model characteristic of IVD and life sciences tool companies. Distribution combines direct sales in China with international distributor partnerships (Gibthai in Thailand, Hongwei Biosciences in Middle East), joint laboratory arrangements with strategic partners such as Boao Jingding, and an active trade show strategy (Medlab Middle East, China International Import Expo, WHX Labs Dubai).

Key strategic milestones include NMPA Class III medical device registration for Salus Pro (February 2025, registration number 国械注准20253220191) and Saluseq Nimbo (December 2025, 国械注准20253222564), the latter positioned as China's first NMPA-approved small rapid sequencer covering both human and microbial DNA and RNA samples clinically. The company has raised over USD 20 million cumulatively across multiple rounds, including a Series A+ led by Fosun Pharma in May 2025 and a Series B1 of over USD 7 million led by AmoyDx in October 2025. It was recognized as a Shenzhen Potential Unicorn Enterprise in July 2025, approved as a postdoctoral innovation practice base, and its platforms have supported the publication of over 100 SCI papers with an average impact factor of 10.9 in journals including Science and Nature Methods.

Name

Salus BioMed

Legal name

深圳赛陆医疗科技有限公司

Website

https://salus-bio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Shenzhen-based Salus BioMed develops proprietary next-generation gene sequencing platforms (Saluseq Nimbo, Pro, EVO) and spatial transcriptomics solutions for clinical diagnostics, academic research, and public health applications in China and select international markets.

Ownership category

akta.pro rank

Product category

Gene Sequencing Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Gene sequencing instruments
• Spatial transcriptomics
• Next-generation sequencing
• Clinical diagnostic platforms
• Spatial omics solutions

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Gene Sequencing Instruments and Consumables: Sale of proprietary gene sequencing platforms (Saluseq Nimbo, Salus Pro, Salus EVO) and associated consumables/reagents for sequencing runs. Instruments sold with recurring consumable revenue model typical of IVD/life sciences tool companies.
2. Spatial Transcriptomics Solutions: Sale of spatial transcriptomics platforms and reagents including the SalusSTS solution for subcellular resolution tissue analysis.
3. Clinical Diagnostic Applications: Revenue from clinical applications of sequencing platforms including reproductive health, tumor diagnosis, infectious disease control, and large health sectors, enabled by NMPA regulatory approvals.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Salus BioMed (Shenzhen Salus Medical Technology Co., Ltd. / 深圳赛陆医疗科技有限公司) develops and manufactures proprietary gene sequencing instruments (Saluseq Nimbo low-throughput, Salus Pro mid-throughput, Salus EVO high-throughput) using reversible terminator sequencing chemistry, along with a spatial transcriptomics solution (SalusSTS) that integrates high-throughput sequencing with super-resolution fluorescence imaging for subcellular-level analysis. The products serve clinical diagnostics, life sciences research, public health, molecular breeding, and consumer genomics applications, with both Saluseq Nimbo and Salus Pro holding NMPA Class III medical device registrations for clinical use in China.

Product overview

Salus BioMed is a global leading provider of genetic sequencing and spatial transcriptomics solutions. The company offers a complete product portfolio comprising three generations of sequencing platforms: Saluseq Nimbo (low-throughput, rapid sequencer), Salus Pro (mid-throughput flexible sequencer), and Salus EVO (high-throughput sequencer), providing comprehensive coverage across low, mid, and high-throughput sequencing applications. Additionally, the company provides spatial transcriptomics solutions including SalusSTS, achieving sub-micron resolution for subcellular-level analysis. The products are designed for clinical diagnostics (reproductive health, tumor diagnosis, infectious disease control), public health and safety, basic research, molecular breeding, and consumer genomics applications.

Differentiator

Problem solved

Functional benefit

Brands

• Saluseq Nimbo: Low-throughput gene sequencer with rapid 3.4-hour sequencing capability, approved by NMPA for clinical use covering both human and microbial DNA and RNA samples.
• Salus Pro
• Salus EVO
• SalusSTS
• 空间转录组 (Spatial Transcriptomics)

Products and services

• Saluseq Nimbo A small, rapid low-throughput gene sequencer based on the reversible terminator sequencing method with a 3.4-hour turnaround time. NMPA Class III certified (registration 国械注准20253222564) as China's first approved small rapid sequencer clinically covering both human and microbial DNA and RNA samples. Designed for clinical diagnostics and rapid pathogen detection.
• Salus Pro A flexible mid-throughput gene sequencing platform with dual sequencing units supporting multiple chip specifications (80M to 1000M reads) and read lengths (SE50, SE75, SE100, PE100, PE150) in both standard and rapid modes. NMPA Class III certified for clinical applications. Designed for hospitals, clinical testing labs, and research institutions requiring flexible throughput.
• Salus EVO High-throughput gene sequencing platform forming part of Salus BioMed's complete sequencing solution portfolio alongside Salus Pro and Saluseq Nimbo, providing comprehensive coverage across low, mid, and high-throughput sequencing applications for research and clinical customers.
• SalusSTS Spatial Transcriptomics Solution A spatial transcriptomics whole solution achieving approximately 1 micrometer resolution by integrating proprietary high-throughput sequencing with super-resolution fluorescence imaging. Enables researchers to interpret cell-to-cell interactions, cell communication, and functional expression at the subcellular level. Applicable to tumor, developmental, neuroscience, pathology, and immunology fundamental research.

Named customers9 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Hongwei Biosciences (宏微特斯)minorChannel Partner/ Reseller/ Distributor · 1 November 2025Partnered with Hongwei Biosciences (宏微特斯) to exhibit together at Medlab Middle East 2024 in Dubai, showcasing Salus Pro high-throughput sequencer and spatial transcriptomics overall solution to Middle East and international markets.
• Boao Jingding (博奥晶典)coreStrategic or Co-development Partner · 1 October 2025Salus BioMed and Boao Jingding established a joint intelligent high-throughput sequencing laboratory in October 2025. The partnership combines Salus BioMed's high-throughput sequencing equipment R&D and manufacturing capabilities with Boao Jingding's clinical and market resources, forming 'technology + application scenario' synergy to promote the landing of single-cell spatiotemporal omics technology from research to clinical applications.
• Kasetsart University / Gibthai (泰国农业大学 / Gibthai)minorChannel Partner/ Reseller/ Distributor · 1 August 2025Salus Pro was installed at Kasetsart University in Thailand through partnership with Gibthai. The Kasetsart University-Salus BioMed-Gibthai Excellence Center (KSGtEC) was established for life sciences and biomedical research, using Salus Pro as the core sequencing platform. Demonstrates international market validation of Salus BioMed's product strength.
• Single Cell Omics and Health Research Center, Xi'an Jiaotong UniversitycoreStrategic or Co-development Partner · 1 July 2024Strategic partnership established at the Third Single Cell Spatiotemporal Omics and Application Forum in July 2024. Salus BioMed provides its proprietary high-throughput sequencing platform and high-resolution spatial transcriptomics platform. Both parties committed to developing single-cell spatiotemporal omics data analysis technical methods and building a reliable and flexible data analysis and visualization sharing platform.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• BGI Genomics: BGI Genomics is the dominant Chinese genomics services and instruments provider, parent of MGI Tech, and a broad incumbent with extensive sequencing services, clinical diagnostics, and research collaborations. It competes with Salus across both instrument sales and downstream sequencing service markets in China.
• Thermo Fisher Scientific: Thermo Fisher offers the Ion Torrent sequencing platform and is a broad life sciences tools incumbent with deep clinical and research customer relationships. Competes with Salus in clinical sequencing, particularly through its applied biosystems franchise.
• Illumina: Illumina is the global leader in next-generation sequencing with the dominant installed base worldwide. Its NovaSeq, NextSeq, and iSeq platforms compete with Salus's full throughput range, and Illumina's reagent consumables ecosystem represents both a competitive threat and the benchmark Salus is targeting to displace in China.

Emerging players

• Ultima Genomics: Ultima Genomics is an emerging sequencing platform company targeting high-throughput, low-cost sequencing using novel open-flow architectures. Its disruptive cost-focused positioning parallels Salus's value proposition in the Chinese clinical and research sequencing market.
• Element Biosciences: Element Biosciences is an emerging sequencing platform company (AVITI) competing on price-performance in the mid-throughput segment — directly overlapping with Salus Pro's positioning as a flexible, cost-effective clinical sequencer.
• Oxford Nanopore Technologies: Oxford Nanopore offers an alternative long-read sequencing platform (MinION, PromethION) that competes with Salus in research and clinical applications, particularly infectious disease surveillance. Both companies emphasize rapid, flexible sequencing with expanding clinical use cases.
• Vizgen: Vizgen develops MERFISH-based spatial transcriptomics platforms (MERSCOPE) with sub-cellular resolution, directly comparable to Salus BioMed's SalusSTS. Both companies target single-cell and spatial biology research markets with high-resolution imaging-based transcriptomics solutions.
• Pacific Biosciences: PacBio provides high-fidelity long-read sequencing (Revio, Sequel II) competing in the research and clinical genomics market. Salus's high-throughput Salus EVO platform and PacBio's systems target overlapping customers in translational research and clinical applications.

Direct peers

• MGI Tech: MGI Tech, a BGI Group spin-off, is a direct competitor developing DNBSEQ sequencing platforms (low, mid, and high-throughput) and competing head-to-head in the Chinese clinical sequencing market. Both companies target domestic substitution of imported sequencers and offer similar instrument + consumable business models.
• 10x Genomics: 10x Genomics is a leading provider of single-cell and spatial omics solutions (Visium, Xenium, Chromium), directly comparable to Salus BioMed's SalusSTS spatial transcriptomics platform. Both companies serve the same life sciences research and translational research customers with spatial biology workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/salus-biomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salus BioMed